Abstract:
The development of smart polymeric nanocarriers has significantly advanced the field of novel drug delivery systems, enabling precise spatial and temporal control over therapeutic release. These systems are engineered to respond to specific physiological or external stimuli, such as pH, temperature, enzymes, and redox conditions, thereby enhancing drug efficacy while minimizing systemic toxicity.
This presentation explores the design and application of stimuli-responsive polymeric nanocarriers, with a focus on their role in improving the therapeutic index of conventional and biologic drugs. Polymeric systems such as micelles, dendrimers, nanogels, and polymer-drug conjugates will be examined in terms of their structural characteristics, drug loading capacity, and release kinetics. The selection of biocompatible and biodegradable polymers, including poly(lactic-co-glycolic acid) (PLGA), polyethylene glycol (PEG), and chitosan, is critical to ensuring safety and clinical translation.
A key highlight of this session is the concept of “smart” delivery, wherein nanocarriers are designed to release their payload in response to disease-specific microenvironments. For instance, tumor tissues often exhibit acidic pH and elevated levels of certain enzymes, which can be exploited to trigger drug release selectively at the site of action. Similarly, redox-sensitive systems leverage the higher intracellular glutathione concentrations to achieve targeted intracellular delivery.
The integration of targeting ligands, such as antibodies, peptides, and aptamers, further enhances the specificity of polymeric nanocarriers. Active targeting strategies enable selective binding to overexpressed receptors on diseased cells, facilitating receptor-mediated endocytosis and improved therapeutic outcomes. The session will also discuss the challenges associated with ligand stability, immunogenicity, and large-scale production.
Recent advances in hybrid systems that combine polymeric carriers with inorganic materials, such as gold nanoparticles or magnetic nanoparticles, have opened new possibilities for theranostics—simultaneous therapy and diagnostics. These multifunctional platforms enable real-time monitoring of drug delivery and therapeutic response, paving the way for personalized medicine.
Clinical translation of smart nanocarriers requires careful consideration of pharmacokinetics, biodistribution, and regulatory requirements. While several polymer-based formulations have received regulatory approval, many advanced systems remain in preclinical or early clinical stages. Barriers such as batch-to-batch variability, complex manufacturing processes, and long-term safety concerns must be addressed to facilitate commercialization.
In summary, smart polymeric nanocarriers represent a promising frontier in pharmaceutics, offering innovative solutions to longstanding challenges in drug delivery. By harnessing the principles of stimuli responsiveness and targeted delivery, these systems have the potential to transform therapeutic paradigms across a wide range of diseases. This session will provide a comprehensive overview of current technologies, clinical progress, and future opportunities in this dynamic field.